Lixte Biotechnology Holdings Company Profile (NASDAQ:LIXT)

About Lixte Biotechnology Holdings (NASDAQ:LIXT)

Lixte Biotechnology Holdings logoLixte Biotechnology Holdings, Inc., including its subsidiary, Lixte Biotechnology, Inc., is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs compounds to attack those targets. The Company's primary focus is developing new treatments for human cancers. The Company designs drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. This approach has led to the development of over two classes of drugs for the treatment of cancer, consisting of protein phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. Compounds of both types also have use in the prevention and treatment of neurodegenerative diseases.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:LIXT
  • CUSIP: N/A
  • Web: www.lixte.com/
Average Prices:
  • 52 Week Range: $0.09 - $0.42
P/E:
  • Trailing P/E Ratio:
  • P/E Growth:
Profitability:
  • Return on Assets: -78.67%
 

Frequently Asked Questions for Lixte Biotechnology Holdings (NASDAQ:LIXT)

What is Lixte Biotechnology Holdings' stock symbol?

Lixte Biotechnology Holdings trades on the NASDAQ under the ticker symbol "LIXT."

How were Lixte Biotechnology Holdings' earnings last quarter?

Lixte Biotechnology Holdings Inc (NASDAQ:LIXT) posted its earnings results on Friday, November, 4th. The company reported ($0.01) earnings per share for the quarter. View Lixte Biotechnology Holdings' Earnings History.

Who are some of Lixte Biotechnology Holdings' key competitors?

Who are Lixte Biotechnology Holdings' key executives?

Lixte Biotechnology Holdings' management team includes the folowing people:

  • John S Kovach, Chief Executive Officer, Chief Financial Officer, Director
  • Stephen J. Forman, Director
  • Philip F. Palmedo, Independent Director

How do I buy Lixte Biotechnology Holdings stock?

Shares of Lixte Biotechnology Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lixte Biotechnology Holdings' stock price today?

One share of Lixte Biotechnology Holdings stock can currently be purchased for approximately $0.15.


MarketBeat Community Rating for Lixte Biotechnology Holdings (NASDAQ LIXT)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  30
MarketBeat's community ratings are surveys of what our community members think about Lixte Biotechnology Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Lixte Biotechnology Holdings (NASDAQ:LIXT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Lixte Biotechnology Holdings (NASDAQ:LIXT)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Lixte Biotechnology Holdings (NASDAQ:LIXT)
Earnings by Quarter for Lixte Biotechnology Holdings (NASDAQ:LIXT)
Earnings History by Quarter for Lixte Biotechnology Holdings (NASDAQ LIXT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016Q3 2016($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lixte Biotechnology Holdings (NASDAQ:LIXT)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Lixte Biotechnology Holdings (NASDAQ:LIXT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Lixte Biotechnology Holdings (NASDAQ:LIXT)
Insider Trades by Quarter for Lixte Biotechnology Holdings (NASDAQ:LIXT)
Insider Trades by Quarter for Lixte Biotechnology Holdings (NASDAQ:LIXT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/11/2017Gil SchwartzbergMajor ShareholderBuy1,005,556$0.06$60,333.36View SEC Filing  
2/19/2016Eric Formanmajor shareholderBuy53,500$0.30$16,050.00View SEC Filing  
2/4/2016Eric Formanmajor shareholderBuy2,500$0.25$625.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Lixte Biotechnology Holdings (NASDAQ:LIXT)
Latest Headlines for Lixte Biotechnology Holdings (NASDAQ:LIXT)
Source:
DateHeadline
finance.yahoo.com logoLixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model
finance.yahoo.com - April 17 at 10:29 AM
finance.yahoo.com logoLate-Breaking Abstract on LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
finance.yahoo.com - March 9 at 6:06 PM
biz.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - January 16 at 1:18 PM
finance.yahoo.com logoFirst-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
finance.yahoo.com - January 16 at 1:18 PM
biz.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - May 17 at 3:14 PM
finance.yahoo.com logoTraumatic Brain Injury Pipeline Market H1 2016 Review Research
finance.yahoo.com - April 11 at 4:40 PM
thestreet.com logoTraumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
www.thestreet.com - April 8 at 7:19 AM
finance.yahoo.com logoSepsis Therapeutics Pipeline Review, H1 2016 - Research and Markets
finance.yahoo.com - March 23 at 3:46 PM
biz.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 3 at 4:40 PM
finance.yahoo.com logoLixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
finance.yahoo.com - February 3 at 10:00 AM
biz.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale
biz.yahoo.com - January 26 at 6:02 AM
finance.yahoo.com logoLixte Completes Private Placement of Convertible Preferred Stock
finance.yahoo.com - January 25 at 10:30 AM
finance.yahoo.com logoLixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University
finance.yahoo.com - January 4 at 8:05 PM
biz.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statemen
biz.yahoo.com - December 30 at 3:27 PM
finance.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. Financials
finance.yahoo.com - December 8 at 1:17 PM
biz.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Financial Statements and Exhibits
biz.yahoo.com - November 10 at 6:05 AM
finance.yahoo.com logoLixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity
finance.yahoo.com - November 6 at 12:30 PM
finance.yahoo.com logoLixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds
finance.yahoo.com - September 17 at 1:00 PM
biz.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - August 7 at 6:08 PM
biz.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 27 at 4:46 PM

Social

Chart

Lixte Biotechnology Holdings (LIXT) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff